496786-98-2

Basic information

• Product Name: 4-[5-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PYRIDIN-2-YL]-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: TERT-BUTYL 4-[5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-2-PYRIDINYL]TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE;TERT-BUTYL 4-[5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-YL]PIPERAZINE-1-CARBOXYLATE;6-(4-TERT-BUTOXYCARBONYLPIPERAZINYL)PYRIDINE-3-BORONIC ACID, PINACOL ESTER;4-(5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-YL)-1-BOC-PIPERAZINE;4-[5-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PYRIDIN-2-YL]-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;2-(4-BOC-PIPERAZINE)PYRIDINE-5-BORONIC ACID PINACOL ESTER;2-(4-BOC-PIPERAZIN-1-YL)PYRIDINE-5-BORONIC ACID PINACOL ESTER;2-(4-TERT-BUTOXYCARBONYLPIPERAZIN-1-YL)PYRIDINE-5-BORONIC ACID, PINACOL ESTER
• CAS NO: 496786-98-2
• Molecular Formula: C₂₀H₃₂BN₃O₄
• Molecular Weight: 389.3
• Product Categories: Heterocyclic Compounds;Boronic ester;Organoborons;Pyridine
• Mol File: 496786-98-2.mol

Chemical Properties

• Melting Point: 165-169 °C
• Boiling Point: 515.9 °C at 760 mmHg
• Flash Point: 265.8 °C
• Appearance: /
• Density: 1.14 g/cm³
• Vapor Pressure: 9.48E-11mmHg at 25°C
• Refractive Index: 1.536
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 8.41±0.31(Predicted)
• CAS DataBase Reference: 4-[5-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PYRIDIN-2-YL]-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[5-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PYRIDIN-2-YL]-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(496786-98-2)
• EPA Substance Registry System: 4-[5-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PYRIDIN-2-YL]-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(496786-98-2)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 22-24/25
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 496786-98-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-[5-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester is used as a synthetic intermediate for the development of new pharmaceuticals. Its unique structure allows for the creation of diverse drug candidates with potential applications in various therapeutic areas.
Used in Chemical Research:
In the field of chemical research, 4-[5-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PYRIDIN-2-YL]-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER serves as a valuable building block for the synthesis of more complex molecules. Its reactivity and structural features make it a useful tool for exploring new chemical reactions and developing novel synthetic methodologies.
Used in Fluorogenic Probes:
4-[5-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester is used as a reactant in the preparation of fluorogenic probes. These probes are designed to detect and distinguish chemical warfare agents and their mimics, providing a valuable tool for environmental monitoring and safety.

InChI:InChI=1/C20H32BN3O4/c1-18(2,3)26-17(25)24-12-10-23(11-13-24)16-9-8-15(14-22-16)21-27-19(4,5)20(6,7)28-21/h8-9,14H,10-13H2,1-7H3

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 153747-97-8 5-Bromo-2-(4-tert-butoxycarbonylpiperazin-1-yl)pyridine 
• 73406-97-0 5-bromo-2-(piperazin-1-yl)pyridine 
• 53939-30-3 5-bromo-2-chloropyridine 
• 766-11-0 5-bromo-2-fluoropyridine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 25240-59-9 pinacolboronic acid 

Downstream Products

• 1323919-74-9 4-{5'-[2-(5-chloro-2-fluoro-phenyl)-[1,8]naphthyridin-4-yl]-[3,3']bipyridinyl-6-yl}-piperazine-1-carboxylic acid tert-butyl ester 
• 1383481-17-1 tert-butyl 4-(5-{3-[3-({[(2,2,2-trifluoroethyl)amino]carbonyl}amino)phenyl]imidazo[1,2-b]pyridazin-7-yl}pyridin-2-yl)piperazine-1-carboxylate 
• 1379522-33-4 tert-butyl 4-(5-{[4-(methylsulfonyl)benzyl]oxy}pyridin-2-yl)piperazine-1-carboxylate 
• 1419063-03-8 tert-butyl 4-(5-(4-(1-(2-cyano-1,2-dimethylhydrazinyl)-4-methyl-1-oxopentan-2-ylcarbamoyl)phenyl)pyridin-2-yl)piperazine-1-carboxylate 
• 1419063-02-7 tert-butyl 4-(5-(3-(1-(2-cyano-1,2-dimethylhydrazinyl)-4-methyl-1-oxopentan-2-ylcarbamoyl)phenyl)pyridin-2-yl)piperazine-1-carboxylate 
• 1431703-21-7 C₃₉H₅₄N₆O₅Si 
• 1654738-73-4 C₄₁H₄₈F₂N₈O₅ 
• 1613643-22-3 C₃₁H₃₂F₂N₈O 
• 1613643-71-2 C₂₀H₂₅FN₄O₂ 

Relevant articles and documents

3-substituent-5-(substituted aryl)-7-azaindole derivative and application thereof

The invention discloses a 3-substituent-5-(substituted aryl)-7-azaindole derivative and application thereof. The structural formula of the 3-substituent-5-(substituted aryl)-7-azaindole derivative is shown in the specification, and the 3-substituent-5-(substituted aryl)-7-azaindole derivative has obvious anti-coronavirus activity. In-vitro binding experiments show that the 3-substituent-5-(substituted aryl)-7-azaindole derivative disclosed by the invention generally has relatively strong affinity with a drug target 3CLPro protease of coronavirus, can effectively inhibit the activity of the 3CLPro protease, and is a small molecular ligand for targeted inhibition of 3CLPro.

HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF

The present invention relates to a heterocyclic compound, a pharmaceutical composition comprising same, a preparation method therefor, and a use thereof. Specifically, the compound of the present invention is represented by formula (I), and used for preventing or treating a disease or condition related to RET activity.

1,5,7-TRISUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES

The present disclosure relates to 1,5,7-trisubstituted isoquinoline derivatives, their preparation and pharmaceutical use. In particular, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. The definitions of the groups in the formula can be found in the specification and claims.

Substituted pyridine compound and its method and use thereof

The invention relates to a novel substitutive pyridine compound, and a pharmaceutically acceptable salt and a pharmaceutical preparation of the substitutive pyridine compound for regulating the activity of protein kinases and regulating signal responses between cells or in the cells. Meanwhile, the invention further relates to a pharmaceutical composition containing the compound provided by the invention, and a method for treating high proliferative diseases of mammals, especially human with the pharmaceutical composition.

PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS

The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

HETEROCYCLIC COMPOUNDS

The present invention provides a heterocyclic compound a TLR7 and/or TLR9 and/or TLR-7/8/9 and/or TLR-7/8 and/or TLR-7/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases and/or inflammatory diseases and the like, in particular, acute decompensated heart failure, non-alcoholic steatohepatitis (NASH), IgA nephropathy, Duchenne muscular dystrophy (DMD), systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, transplant rejection and graft-versus-host disease, hepatocellular carcinoma (HCC) and the like. The present invention is a compound represented by the formula (1) : wherein each symbol is as described in the specification, or a salt thereof.

PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS

The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

PDE 10a Inhibitors for the Treatment of Type II Diabetes

Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: wherein R1, R2, L, and Q are defined herein.

3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS

The present application relates to novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to pharmaceutically acceptable salts and compositions comprising the said novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives and their use in the treatment of various disorders.

Pyridine Derivative and Medicinal Agent

A main object of the present invention is to provide a novel pyridine derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof. In formula [1], R represents an aryl group or a heteroaryl group, which may be